Secretin/vasoactive intestinal peptide-stimulated secretion of bombesin/gastrin releasing peptide from human small cell carcinoma of the lung.
Bombesin/gastrin releasing peptide-like immunoreactivity (BLI) is found in the majority of small cell carcinoma of the lung (SCCL) cell lines examined. Because BLI is present in high concentration in SCCL we studied the mechanism of BLI secretion from several SCCL cell lines and in patients with SCCL. In cell line NCI-H345 the structurally related polypeptide hormones secretin, vasoactive intestinal peptide, and peptide histidine isoleucine as well as theophylline, a phosphodiesterase inhibitor, N6,O2'-dibutyryl cyclic adenosine 3':5'-monophosphate, a cyclic nucleotide analogue, increased BLI release by 16-120% and cyclic adenosine 3':5'-monophosphate by 36-350%. Similar results were obtained in SCCL cell line NCI-H209. i.v. injection of secretin (2 units/kg) significantly increased plasma BLI in 2 patients with extrapulmonary SCCL. These data suggest that SCCL cells possess receptors for secretin/vasoactive intestinal peptide and that receptor occupation stimulates in vitro and in vivo BLI secretion.
D000527:Alprostadil / Q000494:pharmacology; D001839:Bombesin / Q000378:metabolism*; D003994:Bucladesine / Q000494:pharmacology; D018288:Carcinoma, Small Cell / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism; D019886:Gastrin-Releasing Peptide; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism*; D010451:Peptide PHI; D010455:Peptides / Q000378:metabolism* / Q000494:pharmacology; D012633:Secretin / Q000494:pharmacology*; D012636:Secretory Rate / Q000187:drug effects*; D013806:Theophylline / Q000494:pharmacology; D013997:Time Factors; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D010451:Peptide PHI; D010455:Peptides; D012633:Secretin; D014660:Vasoactive Intestinal Peptide; D003994:Bucladesine; D019886:Gastrin-Releasing Peptide; D013806:Theophylline; D000242:Cyclic AMP; D000527:Alprostadil; D001839:Bombesin